ZA200705472B - [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl) methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders - Google Patents

[4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl) methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders

Info

Publication number
ZA200705472B
ZA200705472B ZA200705472A ZA200705472A ZA200705472B ZA 200705472 B ZA200705472 B ZA 200705472B ZA 200705472 A ZA200705472 A ZA 200705472A ZA 200705472 A ZA200705472 A ZA 200705472A ZA 200705472 B ZA200705472 B ZA 200705472B
Authority
ZA
South Africa
Prior art keywords
glyt
piperazin
neurological
heteroaryl
inhibitors
Prior art date
Application number
ZA200705472A
Other languages
English (en)
Inventor
Jolidon Synese
Norcross Roger David
Narquizian Robert
Pinard Emmanuel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200705472B publication Critical patent/ZA200705472B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200705472A 2005-01-07 2007-07-04 [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl) methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders ZA200705472B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05100077 2005-01-07

Publications (1)

Publication Number Publication Date
ZA200705472B true ZA200705472B (en) 2008-09-25

Family

ID=35998949

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705472A ZA200705472B (en) 2005-01-07 2007-07-04 [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl) methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders

Country Status (19)

Country Link
US (1) US7220744B2 (xx)
EP (1) EP1838308B1 (xx)
JP (1) JP5006799B2 (xx)
KR (1) KR100895752B1 (xx)
CN (1) CN101137363B (xx)
AR (1) AR052866A1 (xx)
AT (1) ATE472327T1 (xx)
AU (1) AU2005324024B2 (xx)
BR (1) BRPI0519794A2 (xx)
CA (1) CA2593463C (xx)
DE (1) DE602005022113D1 (xx)
ES (1) ES2346335T3 (xx)
IL (1) IL184353A (xx)
MX (1) MX2007008189A (xx)
NO (1) NO20073667L (xx)
RU (1) RU2396270C2 (xx)
TW (1) TWI313174B (xx)
WO (1) WO2006072436A1 (xx)
ZA (1) ZA200705472B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
AR051091A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CN101083982A (zh) * 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5080256B2 (ja) * 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
KR101143073B1 (ko) 2007-03-05 2012-05-08 에프. 호프만-라 로슈 아게 Ｇｌｙｔ-1 억제제의 합성 방법
JP2012505173A (ja) 2008-10-09 2012-03-01 エフ．ホフマン−ラ ロシュ アーゲー ピロリジンｎ−ベンジル誘導体
TW201127806A (en) * 2009-09-02 2011-08-16 Du Pont Process for the synthesis of fluorinated ethers of aromatic acids
TW201127805A (en) * 2009-09-02 2011-08-16 Du Pont Process for the synthesis of fluorinated ethers of aromatic acids
CN101885708B (zh) * 2010-07-07 2013-03-06 中国科学院上海有机化学研究所 5-多氟烷基取代的2-氨基噻唑类化合物、合成方法及其应用
WO2011082660A1 (zh) * 2010-01-08 2011-07-14 中国科学院上海有机化学研究所 5-多氟烷基取代的2-氨基噻唑类化合物、合成方法及其应用
AU2011261375B2 (en) * 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
CA2841037C (en) * 2011-08-17 2020-03-31 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
CN104119343A (zh) * 2013-04-25 2014-10-29 苏州科捷生物医药有限公司 2-三氟甲基噻二唑类化合物及其用途
KR102288648B1 (ko) * 2013-06-19 2021-08-12 유니버시티 오브 유타 리서치 파운데이션 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
CN105712952B (zh) * 2014-12-22 2021-03-26 上海翰森生物医药科技有限公司 2-取代氧基-5-甲砜基苯基哌嗪酰胺类似物及其制备方法和用途
CN105712945B (zh) * 2014-12-22 2020-12-01 上海翰森生物医药科技有限公司 2-取代氧基-5-甲砜基芳基哌嗪酰胺类似物及其制备方法和用途
CN117777121A (zh) 2016-10-24 2024-03-29 詹森药业有限公司 化合物及其用途
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
JP2022531932A (ja) 2019-05-10 2022-07-12 デシフェラ・ファーマシューティカルズ，エルエルシー ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
CN114258318A (zh) 2019-06-17 2022-03-29 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB867273A (en) * 1959-02-20 1961-05-03 Wallace & Tiernan Inc Piperazine derivatives
DE2423847A1 (de) 1973-05-28 1975-01-02 Ciba Geigy Ag Neue sulfamoylbenzoesaeureamide
DE2611705A1 (de) 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
PL343435A1 (en) * 1998-03-06 2001-08-13 Janssen Pharmaceutica Nv Glycine transport inhibitors
EP1058684A1 (en) 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
EP1421071B1 (en) 2001-07-02 2009-11-18 High Point Pharmaceuticals, LLC Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators
WO2003035602A1 (fr) 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
EP1554260A1 (en) 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
PT1656361E (pt) * 2003-08-11 2008-03-05 Hoffmann La Roche Piperazina com um grupo fenilo substituído do tipo or e a sua utilização como inibidor de tgli1
ES2294529T3 (es) 2003-09-09 2008-04-01 F. Hoffmann-La Roche Ag Derivados de 1-(2-amino-benzoil)-piperacina como inhibidores de absorcion de glicina para el tratamiento de psicosis.
PL1703909T3 (pl) * 2003-09-09 2009-09-30 Hoffmann La Roche Pochodne 1-benzoilopiperazyny jako inhibitory wychwytu glicyny do leczenia psychoz

Also Published As

Publication number Publication date
CN101137363B (zh) 2010-09-15
DE602005022113D1 (de) 2010-08-12
AU2005324024A1 (en) 2006-07-13
JP2008526796A (ja) 2008-07-24
MX2007008189A (es) 2007-08-07
RU2396270C2 (ru) 2010-08-10
AR052866A1 (es) 2007-04-11
BRPI0519794A2 (pt) 2009-03-17
EP1838308A1 (en) 2007-10-03
IL184353A0 (en) 2007-10-31
JP5006799B2 (ja) 2012-08-22
CN101137363A (zh) 2008-03-05
WO2006072436A1 (en) 2006-07-13
NO20073667L (no) 2007-07-24
US20060167009A1 (en) 2006-07-27
ATE472327T1 (de) 2010-07-15
CA2593463C (en) 2013-10-08
AU2005324024B2 (en) 2011-02-17
KR100895752B1 (ko) 2009-04-30
EP1838308B1 (en) 2010-06-30
IL184353A (en) 2012-06-28
US7220744B2 (en) 2007-05-22
ES2346335T3 (es) 2010-10-14
KR20070092759A (ko) 2007-09-13
TW200635585A (en) 2006-10-16
CA2593463A1 (en) 2006-07-13
RU2007124545A (ru) 2009-02-20
TWI313174B (en) 2009-08-11

Similar Documents

Publication Publication Date Title
ZA200705472B (en) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl) methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
IL174734A0 (en) Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
HK1106247A1 (en) 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
TWI349672B (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
IL173768A0 (en) 1-(2-amino-benzol)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
AP2005003250A0 (en) Heterocyclic substituted piperazines for the treatment of schizophrenia.
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
SI1656347T1 (sl) Substituirani indolni derivati za farmacevtske sestavke za zdravljenje respiratornih bolezni
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
HK1124048A1 (en) 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
EP1740581A4 (en) PYRIDYL DERIVATIVE COMPOUNDS SUBSTITUTED AT POSITIONS 2, 4, 6 USEFUL AS INHIBITORS OF BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
AP2007003891A0 (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-pipe ridine derivatives as pde10 inhibitors for the treatment of cns disorders
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2006004636A3 (en) Fused heterocyclic kinase inhibitors
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
IL185242A0 (en) 3,4-substituted pyrrolidine derivatives for the treatment of hypertension
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2004022528A3 (en) Arylglycine derivatives and their use as glycine transport inhibitors
AU2003242860A8 (en) 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders
IL172126A0 (en) Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection
UA94054C2 (xx) Похідні нітрокатехолу як комт-інгібітори[производные нитрокатехола в качестве комт-ингибиторов